Although induction chemotherapy (IC) is the standard of care in medically fit patients with
newly diagnosed acute myeloid leukemia (AML), limited retrospective data indicate that …

ABSTRACT Objectives The combination of Venetoclax (VEN) and Azacitidine (AZA)
increases survival outcomes and yields excellent responses in patients with acute myeloid …

Simple Summary Patients with myeloid malignancies (blood cancers such as leukemia and
myelodysplastic syndromes) that have returned or worsened despite chemotherapy or a …

In this issue of Blood, Dohner et al, 1 on behalf of the European LeukemiaNet (ELN), present
an update of their guidelines for the diagnosis and management of acute myeloid leukemia …

We review the importance of monocytic differentiation and differentiation induction in non-
APL (acute promyelocytic leukemia) variants of acute myeloid leukemia (AML), a …

Objective To compare the efficacy and safety of venetoclax (VEN) in combination with
chemotherapy (chemo) versus chemo alone in the treatment of acute myeloid leukemia …

Genomic advancements have yielded pivotal insights into hematological neoplasms,
particularly concerning germline predisposition mutations. Following the WHO 2016 …

Despite recent progress, acute myeloid leukemia (AML) remains a disease associated with
poor prognosis, particularly in older AML patients unfit to tolerate intensive chemotherapy …

Acute myeloid leukemia (AML) is an aggressive hematological disease that mainly affects
elderly patients. Following the randomized VIALE-A trial, current standard treatment in …

Simple Summary Now that low-intensity therapies, such as DNA methyltransferase inhibitors
and venetoclax, have emerged as the leading options for elderly patients, it is increasingly …